Enhancing our knowledge of the pathogenesis of prostate cancer and translating it into novel diagnostic methods and therapeutic strategies.
Co-Leader: Cory Abate-Shen, PhD
Co-Leader: Charles Drake, M.D., Ph.D.
This program aims to explore how prostate cancer begins so that individual patients can be treated effectively, and to clarify the complex array of distinct diseases called prostate cancer. The multi-disciplinary team includes basic, translational and clinical scientists, with expertise in molecular and experimental pathology, mouse genetics and modeling, genomics and informatics, as well as clinical trial design and population-based studies. The disease-centered, mechanism-based focus helps to transfer biological discoveries into animal models, preclinical and clinical applications. Clinical applications include novel assays to diagnose cancer and predict its progress, use of molecular signals to guide trials, and a plan that continually adapts experimental treatment to a patient's changing condition.